Gestodene, a novel positive allosteric modulator of PAR1, enhances PAR1-mediated human platelet aggregation
Frontiers in Pharmacology · 26.07.2024 · 15
DOI: 10.3389/fphar.2024.1430548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.07.2024. Verfasst von So-Hyeon Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Protease-activated receptor 1 (PAR1) is expressed in human platelets and can be activated by low concentrations of thrombin. Vorapaxar, a selective antagonist of PAR1, inhibits thrombin-induced calcium mobilization in human platelet, which is associated with an increased risk of bleeding. Conversely, the administration of a positive allosteric modulator (PAM) of PAR1 may pose a substantial risk of thrombosis due to inducing excessive platelet activation. In this study, we discovered a novel PAM of PAR1 and investigated the effect of enhanced PAR1 activation by PAM of PAR1 on platelet activation.
Methods
To find PAMs of PAR1, a cell-based screen was performed in HT29 cells, and finally, gestodene, an oral contraceptive drug (OC), was identified as a novel PAM of PAR1. The mechanism of action of gestodene and its effects on platelet activation were investigated in human megakaryocytic leukemia cell line MEG-01 cells and human platelet.
Results
Gestodene enhanced both thrombin- and PAR1-activating peptide (AP)-induced intracellular calcium levels in a dose-dependent manner without altering PAR2 and PAR4 activity. Gestodene significantly increased PAR1-AP-induced internalization of PAR1 and phosphorylation of ERK1/2, and the enhancing effects were significantly blocked by vorapaxar. Furthermore, gestodene potently increased PAR1-AP induced morphological changes in MEG-01 cells. Remarkably, in human blood, gestodene exerted a robust augmentation of PAR1-AP-induced platelet aggregation, and vorapaxar effectively attenuated the gestodene-induced enhancement of platelet aggregation mediated by PAR1.
Conclusion
Gestodene is a selective PAM of PAR1 and suggest one possible mechanism for the increased risk of venous thromboembolism associated with OCs containing gestodene.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea.
- Integrative Research Institute for Cerebrovascular and Cardiovascular Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon, Republic of Korea.
- Department of Neurology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Park, S. H., Heo, Y., Kwon, I., Jo, S., Jeon, H., Lee, Y., Kim, J., Heo, J. H., & Namkung, W. (2024). Gestodene, a novel positive allosteric modulator of PAR1, enhances PAR1-mediated human platelet aggregation. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1430548
Vancouver
Park SH, Heo Y, Kwon I, Jo S, Jeon H, Lee Y, et al. Gestodene, a novel positive allosteric modulator of PAR1, enhances PAR1-mediated human platelet aggregation. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1430548
BibTeX
@article{Park2024,
author = {Park, So-Hyeon and Heo, Yunkyung and Kwon, Il and Jo, Sungwoo and Jeon, Hyejin and Lee, Yechan and Kim, Jieun and Heo, Ji Hoe and Namkung, Wan},
title = {Gestodene, a novel positive allosteric modulator of PAR1, enhances PAR1-mediated human platelet aggregation},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1430548}
}
EUVIMED